187 related articles for article (PubMed ID: 23665270)
1. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride.
Bird ST; Brophy JM; Hartzema AG; Delaney JA; Etminan M
J Urol; 2013 Nov; 190(5):1811-4. PubMed ID: 23665270
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer.
Duijnhoven RG; Straus SM; Souverein PC; de Boer A; Bosch JL; Hoes AW; De Bruin ML
Cancer Causes Control; 2014 Nov; 25(11):1577-82. PubMed ID: 25135615
[TBL] [Abstract][Full Text] [Related]
3. Lack of Association between 5α-Reductase Inhibitors and Depression.
Dyson TE; Cantrell MA; Lund BC
J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
[TBL] [Abstract][Full Text] [Related]
4. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
5. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
6. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
7. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
8. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
[No Abstract] [Full Text] [Related]
9. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
10. Finasteride: male breast cancer.
Prescrire Int; 2010 Dec; 19(111):283. PubMed ID: 21355383
[No Abstract] [Full Text] [Related]
11. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
Corona G; Rastrelli G; Maseroli E; Balercia G; Sforza A; Forti G; Mannucci E; Maggi M
J Endocrinol Invest; 2012 Nov; 35(10):915-20. PubMed ID: 22777612
[TBL] [Abstract][Full Text] [Related]
13. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
[TBL] [Abstract][Full Text] [Related]
14. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
15. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
16. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
17. Association between 5-alpha reductase inhibition and risk of hip fracture.
Jacobsen SJ; Cheetham TC; Haque R; Shi JM; Loo RK
JAMA; 2008 Oct; 300(14):1660-4. PubMed ID: 18840839
[TBL] [Abstract][Full Text] [Related]
18. Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden.
Kjærulff TM; Ersbøll AK; Green A; Emneus M; Brasso K; Iversen P; Pukkala E; Bolin K; Thygesen LC
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):980-986. PubMed ID: 30842126
[TBL] [Abstract][Full Text] [Related]
19. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
20. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
